Cargando…
Fabrication and Characterisation of 3D-Printed Triamcinolone Acetonide-Loaded Polycaprolactone-Based Ocular Implants
Triamcinolone acetonide (TA) is a corticosteroid that has been used to treat posterior segment eye diseases. TA is injected intravitreally in the management of neovascular disorders; however, frequent intravitreal injections result in many potential side effects and poor patient compliance. In this...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9863928/ https://www.ncbi.nlm.nih.gov/pubmed/36678872 http://dx.doi.org/10.3390/pharmaceutics15010243 |
_version_ | 1784875456554598400 |
---|---|
author | Annuryanti, Febri Domínguez-Robles, Juan Anjani, Qonita Kurnia Adrianto, Muhammad Faris Larrañeta, Eneko Thakur, Raghu Raj Singh |
author_facet | Annuryanti, Febri Domínguez-Robles, Juan Anjani, Qonita Kurnia Adrianto, Muhammad Faris Larrañeta, Eneko Thakur, Raghu Raj Singh |
author_sort | Annuryanti, Febri |
collection | PubMed |
description | Triamcinolone acetonide (TA) is a corticosteroid that has been used to treat posterior segment eye diseases. TA is injected intravitreally in the management of neovascular disorders; however, frequent intravitreal injections result in many potential side effects and poor patient compliance. In this work, a 3D bioprinter was used to prepare polycaprolactone (PCL) implants loaded with TA. Implants were manufactured with different shapes (filament-, rectangular-, and circle-shaped) and drug loadings (5, 10, and 20%). The characterisation results showed that TA was successfully mixed and incorporated within the PCL matrix without using solvents, and drug content reached almost 100% for all formulations. The drug release data demonstrate that the filament-shaped implants (SA/V ratio~7.3) showed the highest cumulative drug release amongst all implant shapes over 180 days, followed by rectangular- (SA/V ratio~3.7) and circle-shaped implants (SA/V ratio~2.80). Most implant drug release data best fit the Korsmeyer–Peppas model, indicating that diffusion was the prominent release mechanism. Additionally, a biocompatibility study was performed; the results showed >90% cell viability, thus proving that the TA-loaded PCL implants were safe for ocular application. |
format | Online Article Text |
id | pubmed-9863928 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98639282023-01-22 Fabrication and Characterisation of 3D-Printed Triamcinolone Acetonide-Loaded Polycaprolactone-Based Ocular Implants Annuryanti, Febri Domínguez-Robles, Juan Anjani, Qonita Kurnia Adrianto, Muhammad Faris Larrañeta, Eneko Thakur, Raghu Raj Singh Pharmaceutics Article Triamcinolone acetonide (TA) is a corticosteroid that has been used to treat posterior segment eye diseases. TA is injected intravitreally in the management of neovascular disorders; however, frequent intravitreal injections result in many potential side effects and poor patient compliance. In this work, a 3D bioprinter was used to prepare polycaprolactone (PCL) implants loaded with TA. Implants were manufactured with different shapes (filament-, rectangular-, and circle-shaped) and drug loadings (5, 10, and 20%). The characterisation results showed that TA was successfully mixed and incorporated within the PCL matrix without using solvents, and drug content reached almost 100% for all formulations. The drug release data demonstrate that the filament-shaped implants (SA/V ratio~7.3) showed the highest cumulative drug release amongst all implant shapes over 180 days, followed by rectangular- (SA/V ratio~3.7) and circle-shaped implants (SA/V ratio~2.80). Most implant drug release data best fit the Korsmeyer–Peppas model, indicating that diffusion was the prominent release mechanism. Additionally, a biocompatibility study was performed; the results showed >90% cell viability, thus proving that the TA-loaded PCL implants were safe for ocular application. MDPI 2023-01-11 /pmc/articles/PMC9863928/ /pubmed/36678872 http://dx.doi.org/10.3390/pharmaceutics15010243 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Annuryanti, Febri Domínguez-Robles, Juan Anjani, Qonita Kurnia Adrianto, Muhammad Faris Larrañeta, Eneko Thakur, Raghu Raj Singh Fabrication and Characterisation of 3D-Printed Triamcinolone Acetonide-Loaded Polycaprolactone-Based Ocular Implants |
title | Fabrication and Characterisation of 3D-Printed Triamcinolone Acetonide-Loaded Polycaprolactone-Based Ocular Implants |
title_full | Fabrication and Characterisation of 3D-Printed Triamcinolone Acetonide-Loaded Polycaprolactone-Based Ocular Implants |
title_fullStr | Fabrication and Characterisation of 3D-Printed Triamcinolone Acetonide-Loaded Polycaprolactone-Based Ocular Implants |
title_full_unstemmed | Fabrication and Characterisation of 3D-Printed Triamcinolone Acetonide-Loaded Polycaprolactone-Based Ocular Implants |
title_short | Fabrication and Characterisation of 3D-Printed Triamcinolone Acetonide-Loaded Polycaprolactone-Based Ocular Implants |
title_sort | fabrication and characterisation of 3d-printed triamcinolone acetonide-loaded polycaprolactone-based ocular implants |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9863928/ https://www.ncbi.nlm.nih.gov/pubmed/36678872 http://dx.doi.org/10.3390/pharmaceutics15010243 |
work_keys_str_mv | AT annuryantifebri fabricationandcharacterisationof3dprintedtriamcinoloneacetonideloadedpolycaprolactonebasedocularimplants AT dominguezroblesjuan fabricationandcharacterisationof3dprintedtriamcinoloneacetonideloadedpolycaprolactonebasedocularimplants AT anjaniqonitakurnia fabricationandcharacterisationof3dprintedtriamcinoloneacetonideloadedpolycaprolactonebasedocularimplants AT adriantomuhammadfaris fabricationandcharacterisationof3dprintedtriamcinoloneacetonideloadedpolycaprolactonebasedocularimplants AT larranetaeneko fabricationandcharacterisationof3dprintedtriamcinoloneacetonideloadedpolycaprolactonebasedocularimplants AT thakurraghurajsingh fabricationandcharacterisationof3dprintedtriamcinoloneacetonideloadedpolycaprolactonebasedocularimplants |